enGene Holdings Inc. Files 8-K Report
Ticker: ENGNW · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1980845
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
enGene Holdings filed an 8-K, mostly standard disclosures and exhibits.
AI Summary
On September 3, 2025, enGene Holdings Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that enGene Holdings Inc. has submitted required regulatory documentation to the SEC, which may contain updates or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report with no immediate indication of significant new risks or material adverse events.
Key Players & Entities
- enGene Holdings Inc. (company) — Registrant
- September 03, 2025 (date) — Date of earliest event reported
- 514 332-4888 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is the exact date of the earliest event reported?
The date of the earliest event reported is September 03, 2025.
What is the company's principal executive office address?
The address of the Principal Executive Offices is 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada, H4R 2P1.
What is the company's telephone number?
The Registrant's Telephone Number, Including Area Code, is 514 332-4888.
Under which jurisdiction is enGene Holdings Inc. incorporated?
enGene Holdings Inc. is incorporated in British Columbia.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-03 07:56:23
Key Financial Figures
- $11.50 — e Common Share, at an exercise price of $11.50 per Share ENGNW The Nasdaq Stock Ma
Filing Documents
- engn-20250903.htm (8-K) — 50KB
- engn-ex99_1.htm (EX-99.1) — 1KB
- engn-ex99_1.pdf (EX-99.1) — 1185KB
- engn-ex99_2.htm (EX-99.2) — 25KB
- img8714134_0.jpg (GRAPHIC) — 15KB
- 0000950170-25-112674.txt ( ) — 1866KB
- engn-20250903.xsd (EX-101.SCH) — 45KB
- engn-20250903_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 3, 2025, enGene Holdings Inc. (the "Company") updated its Corporate Presentation, a copy of which is furnished with this Form 8-K as Exhibit 99.1 and incorporated into this Item 7.01 by reference. The information in this Item 7.01 of Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On September 3, 2025, the Company issued a news release announcing that it achieved its target enrollment of 100 patients in its pivotal cohort ("Cohort 1") of the Phase 2 portion of the LEGEND trial of detalimogene voraplasmid ("detalimogene"). Cohort 1 is studying detalimogene in patients with high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without concomitant papillary disease who are unresponsive to Bacillus Calmette-Gurin. A copy of the news release is filed with this Form 8-K as Exhibit 99.2 and incorporated into this Item 8.01 by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibits 99.1 Corporate Presentation, dated September 3, 2025 . 99.2 Press Release of the Company, dated September 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENGENE HOLDINGS INC. Date: September 3, 2025 By: /s/ Ronald H.W.Cooper Name: Ronald H.W.Cooper Title: Chief Executive Officer and President